FindTrial
Sign In

To establish a preoperative cervical lymph node assessment system for the treatment of cervical cancer (IIB-IVA phase) and to establish a basis for the improvement of surgical pathological staging for IIB-IVA cervical cancer so as to develop treatment guidelines

To establish a preoperative cervical lymph node assessment system for the treatment of cervical cancer (IIB-IVA phase) and to establish a basis for the improvement of surgical pathological staging for IIB-IVA cervical cancer so as to develop treatment guidelines

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015668
Enrollment
Unknown
Registered
2018-04-13
Start date
2017-04-20
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cercal cancer

Interventions

Surgery Group:Laparoscopic exploration and removal of pelvic and abdominal aortic lymph nodes
Control group:Convenience radio-chemotherapy

Sponsors

Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: Aged <70 years old, initial treatment of cervical cancer patients; pathological types include squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma; two women from the Department of Gynecology, deputy chief physician doctors and more than three gynecological examinations to determine clinical staging, according to 2009 FIGO clinical In stages, patients with advanced stage cervical cancer (IIB-IVA stage) were identified; pelvic, abdominal, and chest enhanced CT examinations were performed, except for distant metastases; laparoscopic surgery was able to be tolerated; and informed consent was signed.

Exclusion criteria

Exclusion criteria: Patients with severe medical comorbidities who cannot undergo surgery; History of radiotherapy and chemotherapy; Patients with history of other cancers.

Design outcomes

Primary

MeasureTime frame
DFS;OS;—

Countries

China

Contacts

Public ContactJinwei Miao
miaojinweigyn@163.com+86 18518705638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026